BACKGROUND: Following approval of dimethyl fumarate (DMF), we established a registry of relapsing multiple sclerosis (RMS) patients taking DMF at our community MS center. OBJECTIVE: To track DMF patients' tolerability, disease progression, and lymphopenia. METHODS: Patients prescribed DMF for RMS from March 2013 to March 2016 were prospectively enrolled ( N = 412). Baseline data, clinical relapses, magnetic resonance imaging (MRI) activity, discontinuation, and lymphocyte counts were captured through chart review. RESULTS: The mean age of patients starting DMF was 49.4 ± 12.0 years and 70% transitioned from a previous disease-modifying therapy (DMT). Of the patients, 38% discontinued DMF, 76% of whom discontinued due to side effects. Clinical relapse and MRI activity were low. Comparing patients who transitioned from interferon-β (IFN), glatiramer acetate (GA), or natalizumab (NTZ), patients previously on NTZ had higher rates of relapse than those previously on GA (annualized relapse rate p = 0.039, percent relapse p = 0.021). Grade III lymphopenia developed in 11% of patients. Lymphopenia was associated with older age ( p < 0.001) and longer disease duration ( p < 0.001). CONCLUSION: Given the high rates of lymphopenia and discontinuation, it has become our clinical practice to more closely scrutinize older patients and those with a longer disease duration who are potential candidates for initiating DMF therapy.
BACKGROUND: Following approval of dimethyl fumarate (DMF), we established a registry of relapsing multiple sclerosis (RMS) patients taking DMF at our community MS center. OBJECTIVE: To track DMFpatients' tolerability, disease progression, and lymphopenia. METHODS:Patients prescribed DMF for RMS from March 2013 to March 2016 were prospectively enrolled ( N = 412). Baseline data, clinical relapses, magnetic resonance imaging (MRI) activity, discontinuation, and lymphocyte counts were captured through chart review. RESULTS: The mean age of patients starting DMF was 49.4 ± 12.0 years and 70% transitioned from a previous disease-modifying therapy (DMT). Of the patients, 38% discontinued DMF, 76% of whom discontinued due to side effects. Clinical relapse and MRI activity were low. Comparing patients who transitioned from interferon-β (IFN), glatiramer acetate (GA), or natalizumab (NTZ), patients previously on NTZ had higher rates of relapse than those previously on GA (annualized relapse rate p = 0.039, percent relapse p = 0.021). Grade III lymphopenia developed in 11% of patients. Lymphopenia was associated with older age ( p < 0.001) and longer disease duration ( p < 0.001). CONCLUSION: Given the high rates of lymphopenia and discontinuation, it has become our clinical practice to more closely scrutinize older patients and those with a longer disease duration who are potential candidates for initiating DMF therapy.
Authors: Amber Salter; Samantha Lancia; Gary Cutter; Robert J Fox; Ruth Ann Marrie; Jason P Mendoza; James B Lewin Journal: Int J MS Care Date: 2021-07-09
Authors: Irene Eriksson; Thomas Cars; Fredrik Piehl; Rickard E Malmström; Björn Wettermark; Mia von Euler Journal: Eur J Clin Pharmacol Date: 2017-11-11 Impact factor: 2.953
Authors: Robert T Naismith; Jerry S Wolinsky; Annette Wundes; Christopher LaGanke; Douglas L Arnold; Dragana Obradovic; Mark S Freedman; Mark Gudesblatt; Tjalf Ziemssen; Boris Kandinov; Ilda Bidollari; Maria Lopez-Bresnahan; Narinder Nangia; David Rezendes; Lili Yang; Hailu Chen; Shifang Liu; Jerome Hanna; Catherine Miller; Richard Leigh-Pemberton Journal: Mult Scler Date: 2019-11-04 Impact factor: 6.312
Authors: Trudy L Campbell; Béatrice Jenny Lefaux; Lori Lee Mayer; Marie Namey; Gisela Riemer; Miguel A Robles-Sanchez; Sarah White; Michael Edwards; Charles Minor Journal: J Neurosci Nurs Date: 2020-04 Impact factor: 1.627